DEMLOVÁ, Regina, Šárka KOZÁKOVÁ, Michal ŘIHÁČEK, Dana BUČKOVÁ, Kateřina HORSKÁ, Ondřej WIEWIORKA, Luboš BOUČEK, Iveta SELINGEROVÁ, Martina PODBORSKÁ, Alena KORBEROVÁ, Alena MIKUŠKOVÁ, Jiří ŠTARHA, Miroslava BEŇOVSKÁ, Martin RADINA, Michal RICHTER, Lenka ZDRAŽILOVÁ DUBSKÁ and Dalibor VALÍK. Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice. Frontiers in Medicine. Laussane: Frontiers, 2024, vol. 10, January 2024, p. 1-16. ISSN 2296-858X. Available from: https://dx.doi.org/10.3389/fmed.2023.1236948.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice
Authors DEMLOVÁ, Regina (203 Czech Republic, belonging to the institution), Šárka KOZÁKOVÁ (203 Czech Republic, belonging to the institution), Michal ŘIHÁČEK (203 Czech Republic, belonging to the institution), Dana BUČKOVÁ (203 Czech Republic, belonging to the institution), Kateřina HORSKÁ (203 Czech Republic, belonging to the institution), Ondřej WIEWIORKA (203 Czech Republic, belonging to the institution), Luboš BOUČEK (203 Czech Republic), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Martina PODBORSKÁ (203 Czech Republic, belonging to the institution), Alena KORBEROVÁ (203 Czech Republic), Alena MIKUŠKOVÁ (203 Czech Republic, belonging to the institution), Jiří ŠTARHA (203 Czech Republic, belonging to the institution), Miroslava BEŇOVSKÁ (203 Czech Republic, belonging to the institution), Martin RADINA (203 Czech Republic), Michal RICHTER (203 Czech Republic), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution) and Dalibor VALÍK (203 Czech Republic, belonging to the institution).
Edition Frontiers in Medicine, Laussane, Frontiers, 2024, 2296-858X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.900 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fmed.2023.1236948
UT WoS 001154759700001
Keywords in English creatinine; renal functions; eGFR; urgent care medication; cystatin C
Tags 14110317, 14110516, 14110616
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 16/8/2024 07:32.
Abstract
Background: Assessment of kidney function in emergency settings is essential across all medical subspecialties. Daily assessment of patient creatinine results from emergency medical services showed that some deviated from expected values, implying drug-related interference. Methods: Real-time clinical evaluation of an enzyme method (Roche CREP2) in comparison with the Jaffe gen. 2 method (Roche CREJ2) was performed. During the period of December 2022 and January 2023, we analyzed 8,498 patient samples, where 5,524 were heavily medicated STAT patient specimens, 500 were pediatric specimens, and 2,474 were from a distant general population in a different region using the same methods. Results: In 109 out of 5,524 hospital specimens (1.97%, p < 0.001), the CREP2 value was apparently (25% or more) lower than CREJ2. Suspect interfering medication was found in a sample of 43 out of 46 reviewed patients where medication data were available. This phenomenon was not observed in the general population. Conclusion: In a polymedicated urgent care hospital population, a creatinine enzyme method produces unreliable results, apparently due to multiple drug-related interferences.
Links
CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)
Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research
101059788, interní kód MUName: Central European Advanced Therapy and Immunotherapy Centre
Investor: European Union, Widening participation and strengthening the European Research Area
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 22/8/2024 05:16